Zentiva Secures Majority Voting Rights in APONTIS PHARMA AG Acquisition

Zentiva Expands Influence in Pharmaceuticals with APONTIS PHARMA Acquisition

In a significant development in the pharmaceutical sector, Zentiva AG, the wholly-owned subsidiary of Zentiva Pharma GmbH based in Frankfurt am Main, Germany, announced that it has achieved a remarkable milestone by securing approximately 83.57% of the share capital and around 85.27% of the voting rights in APONTIS PHARMA AG. This accomplishment follows the conclusion of the acceptance period for its voluntary public purchase offer, which ended on November 21, 2024.

Zentiva's CEO, Steffen Saltofte, expressed his satisfaction with the outcome, stating, "We are pleased with the success of our public purchase offer. This milestone marks a significant step forward in our journey to expand our reach and enhance our ability to deliver high-quality, affordable medicines to the people who depend on them every day." He emphasized the importance of combining strengths under a unified ownership structure to drive long-term strategies in health and pharmaceutical care.

However, the settlement of this offer still awaits clearance from the foreign direct investment control in Germany. Zentiva anticipates that the final settlement will occur either in December 2024 or in the first quarter of 2025, indicating a proactive approach in navigating the formalities of such transactions.

About Zentiva

Zentiva is a prominent European platform focused on the development, manufacturing, and provision of high-quality and affordable medicines. With the capability to serve over 100 million individuals across Europe, Zentiva operates four wholly-owned manufacturing sites and collaborates with a network of external manufacturing partners to ensure supply security. Their pharmaceutical offerings primarily cover therapeutic areas such as cardiology, diabetes, oncology, respiratory health, and central nervous system disorders, with continuing efforts to expand their self-care portfolio.

As a privately-owned entity, Zentiva has demonstrated sustainable double-digit growth and continues to work towards ambitious goals over the next five years to enhance both organic and inorganic growth across Europe. The company's workforce, comprising nearly 5,000 dedicated professionals, is united by a shared mission to improve health and well-being for all generations.

Understanding APONTIS PHARMA

APONTIS PHARMA AG stands out in the pharmaceutical industry as a leader in the development of Single Pill combinations in Germany. By consolidating two to three generic active ingredients into a single daily dosage, APONTIS has significantly increased medication adherence. This innovation enhances treatment outcomes and quality of life for patients while minimizing complications, mortality, and overall treatment costs. Numerous international treatment guidelines, including those in the EU and Germany, advocate for Single Pill therapies as the optimal treatment choice.

Since its establishment in 2013, APONTIS PHARMA has been committed to developing and distributing a wide range of Single Pill combinations, particularly for cardiovascular diseases such as hypertension and hyperlipidemia. Their continued focus on improving patient care and pharmaceutical innovations positions them as a vital player in the healthcare landscape.

Conclusion

Zentiva's acquisition of a majority stake in APONTIS PHARMA AG marks a pivotal moment in its mission to broaden its impact in the pharmaceutical market. As the company navigates the final steps of this acquisition, stakeholders can expect enhanced offerings that will ultimately serve to improve patient care. The integration of APONTIS PHARMA's innovative approaches will complement Zentiva's existing resources, setting the stage for a future that prioritizes affordable healthcare solutions across Europe.

For further updates, visit Zentiva's official website or APONTIS PHARMA's site.